A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Bond Avillion 2 Development LP
- Target Recruit Count
- 2517
- Registration Number
- NCT05505734
- Locations
- 🇺🇸
Genesis Clinical Research and Consulting, LLC, Fall River, Massachusetts, United States
🇺🇸Meridian Clinical Research, LLC, Lincoln, Nebraska, United States
🇺🇸Mankato Clinic, Mankato, Minnesota, United States
To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: BDA MDI (PT027) 160/180 μgDrug: Pulmicort Respules 0.5 MG/ML Inhalation Suspension
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Bond Avillion 2 Development LP
- Target Recruit Count
- 12
- Registration Number
- NCT04848662
- Locations
- 🇺🇸
IPS Research, Oklahoma City, Oklahoma, United States
🇺🇸TTS Research, Boerne, Texas, United States
A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma
Phase 3
Completed
- Conditions
- Exercise Induced Bronchospasm
- Interventions
- Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μgCombination Product: Placebo metered-dose inhaler
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Bond Avillion 2 Development LP
- Target Recruit Count
- 60
- Registration Number
- NCT04234464
- Locations
- 🇺🇸
Research Site, Burke, Virginia, United States
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Combination Product: Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose)Drug: Budesonide metered dose inhaler / BD MDI 160 µgCombination Product: Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose)Drug: Albuterol sulfate metered dose inhaler / AS MDI 180 μgOther: Placebo metered-dose inhaler / Placebo MDI
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Bond Avillion 2 Development LP
- Target Recruit Count
- 1001
- Registration Number
- NCT03847896
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: Albuterol sulfate metered-dose inhaler 180 μgCombination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μgCombination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Bond Avillion 2 Development LP
- Target Recruit Count
- 3132
- Registration Number
- NCT03769090
- Locations
- 🇬🇧
Research Site, Wokingham, United Kingdom
A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Bond Avillion 2 Development LP
- Target Recruit Count
- 313
- Registration Number
- NCT03384745
- Locations
- 🇵🇱
Investigative Site, Warszawa, Poland
© Copyright 2025. All Rights Reserved by MedPath